Anixa Biosciences Inc (ANIX) stock
ANIXNasdaqPharmaceutical PreparationsFiscal year ends October 31
$2.71+0.04 (+1.50%)
Close on Nov 18, 2026Market cap $94.21MP/E –Yield –
Anixa Biosciences operating income
Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.
Anixa Biosciences's operating income for the twelve months ending Jul 31, 2026 was -$10.98M. For fiscal 2025 it was -$11.70M. The highest annual figure on record is -$944.76K in fiscal 2015.
Annual operating income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Oct 31, 2025 | -$11.70M | – |
| FY2024 | Oct 31, 2024 | -$13.83M | – |
| FY2023 | Oct 31, 2023 | -$11.01M | – |
| FY2022 | Oct 31, 2022 | -$13.88M | – |
| FY2021 | Oct 31, 2021 | -$13.14M | – |
| FY2020 | Oct 31, 2020 | -$9.98M | – |
| FY2019 | Oct 31, 2019 | -$11.89M | – |
| FY2018 | Oct 31, 2018 | -$14.29M | – |
| FY2017 | Oct 31, 2017 | -$6.08M | – |
| FY2016 | Oct 31, 2016 | -$4.51M | – |
| FY2015 | Oct 31, 2015 | -$944.76K | – |
| FY2014 | Oct 31, 2014 | -$5.04M | – |
| FY2013 | Oct 31, 2013 | -$7.92M | – |
| FY2012 | Oct 31, 2012 | -$4.13M | – |
| FY2011 | Oct 31, 2011 | -$5.03M | – |
| FY2010 | Oct 31, 2010 | -$5.25M | – |
Quarterly operating income
Change is against the same quarter a year earlier.
Periods
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026CQ2 2026 | Jul 31, 2026 | -$2.74M | – |
| Q2 FY2026CQ1 2026 | Apr 30, 2026 | -$2.65M | – |
| Q1 FY2026CQ4 2025 | Jan 31, 2026 | -$2.72M | – |
| Q4 FY2025CQ3 2025 | Oct 31, 2025 | -$2.88M | – |
| Q3 FY2025CQ2 2025 | Jul 31, 2025 | -$2.44M | – |
| Q2 FY2025CQ1 2025 | Apr 30, 2025 | -$3.00M | – |
| Q1 FY2025CQ4 2024 | Jan 31, 2025 | -$3.39M | – |
| Q4 FY2024CQ3 2024 | Oct 31, 2024 | -$3.16M | – |
| Q3 FY2024CQ2 2024 | Jul 31, 2024 | -$3.59M | – |
| Q2 FY2024CQ1 2024 | Apr 30, 2024 | -$3.47M | – |
| Q1 FY2024CQ4 2023 | Jan 31, 2024 | -$3.61M | – |
| Q4 FY2023CQ3 2023 | Oct 31, 2023 | -$3.05M | – |
| Q3 FY2023CQ2 2023 | Jul 31, 2023 | -$2.84M | – |
| Q2 FY2023CQ1 2023 | Apr 30, 2023 | -$2.56M | – |
| Q1 FY2023CQ4 2022 | Jan 31, 2023 | -$2.56M | – |
| Q4 FY2022CQ3 2022 | Oct 31, 2022 | -$3.61M | – |
| Q3 FY2022CQ2 2022 | Jul 31, 2022 | -$2.80M | – |
| Q2 FY2022CQ1 2022 | Apr 30, 2022 | -$3.59M | – |
| Q1 FY2022CQ4 2021 | Jan 31, 2022 | -$3.88M | – |
| Q4 FY2021CQ3 2021 | Oct 31, 2021 | -$4.08M | – |
| Q3 FY2021CQ2 2021 | Jul 31, 2021 | -$4.39M | – |
| Q2 FY2021CQ1 2021 | Apr 30, 2021 | -$2.44M | – |
| Q1 FY2021CQ4 2020 | Jan 31, 2021 | -$2.23M | – |
| Q4 FY2020CQ3 2020 | Oct 31, 2020 | -$2.24M | – |
| Q3 FY2020CQ2 2020 | Jul 31, 2020 | -$2.44M | – |
| Q2 FY2020CQ1 2020 | Apr 30, 2020 | -$2.67M | – |
| Q1 FY2020CQ4 2019 | Jan 31, 2020 | -$2.63M | – |
| Q4 FY2019CQ3 2019 | Oct 31, 2019 | -$2.13M | – |
| Q3 FY2019CQ2 2019 | Jul 31, 2019 | -$2.18M | – |
| Q2 FY2019CQ1 2019 | Apr 30, 2019 | -$2.59M | – |
| Q1 FY2019CQ4 2018 | Jan 31, 2019 | -$4.98M | – |
| Q4 FY2018CQ3 2018 | Oct 31, 2018 | -$5.41M | – |
| Q3 FY2018CQ2 2018 | Jul 31, 2018 | -$5.61M | – |
| Q2 FY2018CQ1 2018 | Apr 30, 2018 | -$1.40M | – |
| Q1 FY2018CQ4 2017 | Jan 31, 2018 | -$1.87M | – |
| Q4 FY2017CQ3 2017 | Oct 31, 2017 | -$1.74M | – |
| Q3 FY2017CQ2 2017 | Jul 31, 2017 | -$1.73M | – |
| Q2 FY2017CQ1 2017 | Apr 30, 2017 | -$1.21M | – |
| Q1 FY2017CQ4 2016 | Jan 31, 2017 | -$1.39M | – |
| Q4 FY2016CQ3 2016 | Oct 31, 2016 | -$913.30K | – |
See a number that looks wrong?